Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome

[1] Altman DG(1994)Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 829-835

[2] Lausen B(2004)Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays Clin Cancer Res 10 5815-5819

[3] Sauerbrei W(1998)Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival Am J Clin Pathol 109 431-438

[4] Schumacher M(1998)Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays J Pathol 184 401-407

[5] Charpin C(1998)bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up J Clin Oncol 16 2025-2031

[6] Dales JP(1997)Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas Hum Pathol 28 289-296

[7] Garcia S(1997)CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up Am J Clin Pathol 107 534-541

[8] Carpentier S(1994)Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators J Natl Cancer Inst 86 1539-1545

[9] Djemli A(2008)Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer Cancer Lett 262 232-238

[10] Andrac L(2007)Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis Int J Oncol 31 49-58

[1] Altman DG(1994)Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 829-835

[2] Lausen B(2004)Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays Clin Cancer Res 10 5815-5819

[3] Sauerbrei W(1998)Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival Am J Clin Pathol 109 431-438

[4] Schumacher M(1998)Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays J Pathol 184 401-407

[5] Charpin C(1998)bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up J Clin Oncol 16 2025-2031

[6] Dales JP(1997)Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas Hum Pathol 28 289-296

[7] Garcia S(1997)CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up Am J Clin Pathol 107 534-541

[8] Carpentier S(1994)Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators J Natl Cancer Inst 86 1539-1545

[9] Djemli A(2008)Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer Cancer Lett 262 232-238

[10] Andrac L(2007)Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis Int J Oncol 31 49-58